Last reviewed · How we verify

NCT06231420

Daily Step Count Using Pedometer for Sarcopenic Management in Patient With Cirrhosis: Randomized Controlled Trial

Status unknown NA Last updated 2 February 2024
What this trial tests

NA trial testing Encourage using pedometer in Sarcopenia in 70 participants. Status unknown.

Timeline
1 February 2024
Primary endpoint
31 January 2025
31 July 2025

Quick facts

Lead sponsorMahidol University
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment70
Start date1 February 2024
Primary completion31 January 2025
Estimated completion31 July 2025
Sites1 location across Thailand

Drugs / interventions tested

Conditions studied

Sponsor

Mahidol University

Who can join

Adults 18 to 75, any sex, with Sarcopenia or Cirrhosis, Liver. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of clinical trial is to compare using pedometer in sarcopenic cirrhotic patients. The main questions it aims to answer are: 1. Did the encourage using pedometer group had higher change of skeletal muscle index (SMI) than discourage using pedometer group? 2. How many of patients who had sarcopenic improvement in both groups at 6 months after enrollment? 3. What is the mortality rate and hospital admission in both groups at 12 months after enrollment?

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Encourage using pedometer

Trials testing the same drug.

Other recruiting trials for Sarcopenia

Currently open trials in the same condition.

Other Mahidol University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06231420.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing